CarlottaB

Radiotherapy–drug combinations need to move earlier in the development pipeline to truly maximise patient benefit. Check the new ESTRO Focus Group Policy Review. Read the full article: sciencedirect.com/science/articl… #ESTRO #Radiotherapy #RadOnc #OncoTwitter 📄🎯

In just 2 days, we unite voices, visions, and values for better breast cancer care. Let’s move From Controversies to Consensus together. #wci2025 #CancerCareInnovation #HealthcareProfessionals #CancerCare #MedicalEvents #OncologyExperts #breastcancerawareness

The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin 🔹 DESTINY-Breast11 – Neoadjuvant T-DXd ± THP vs SOC for high-risk HER2+ eBC (291O) 🔹 DESTINY-Breast05 – T-DXd vs T-DM1 in HER2+ primary BC with residual disease after NAT (LBA1) 🔹 ASCENT-03 – SG vs chemo in previously untreated advanced TNBC not eligible for PD-(L)1i (LBA20) 🔹 monarchE – Primary OS results: adjuvant abemaciclib + ET for HR+/HER2− high-risk eBC (LBA13) 🔹 NATALEE – 5-year outcomes of adjuvant ribociclib + NSAI in HR+/HER2− eBC (LBA14) 🔹 POSITIVE – 5-year follow-up on pregnancy after interrupting endocrine therapy (LBA12) 🔹 DESTINY-Breast09 – T-DXd + pertuzumab vs THP in HER2+ a/mBC: subgroup analyses (LBA18) 🔹 REaCT-Hold BMA – Continuing vs de-escalating bone-modifying agents in bone mets (2800O) 🔹 VIKTORIA-1 – Gedatolisib + fulvestrant ± palbociclib vs fulvestrant in HR+/HER2− ABC (LBA17) 🔹 A-BRAVE – Adjuvant avelumab by TILs for high-risk TNBC (323MO) @matteolambe @aftimosp @E_de_Azambuja @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @MammaMiaMagazin @itrisabel @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco

Heart matters!🫀❤️ #Cardioprotection in #anthracycline treated #BreastCancer patients: final analysis from the 2x2 randomized, placebo-controlled, double-blind SAFE trial Article link: authors.elsevier.com/sd/article/S20… @UNI_FIRENZE @AOUCareggi @ESMO_Open @OncoAlert #OncoAlert

My #RadOnc ⚛️ physics team is the BEST! 👏🏻Big thanks to Prof. @LiviaMarrazzo for today’s inspiring overview on Automated treatment planning for breast cancer. Truly beaming with gratitude & hope! 🌟💪 #Innovation #CancerCare #ESTRO2025

Amazing @PierluigiBonomo at the meet the expert session on head and neck guidelines in delineation #ESTRO25 ROs essential in the preoperative decision making process #radonc #OncoAlert @OncoAlert

Proud of @CarlottaB - Honoured to present on behalf of the #BRCABCYcollaboration led by @matteolambe @UNI_FIRENZE @AOUCareggi #ESTRO25 to optimise loco-regional therapy in young #BRCA carriers with #BreastCancer @OncoAlert @ESTRO_RT @UniGenova @SanMartino_Ge @BlondeauxEva

At #ECHNO 2025: where we talk heads, necks, and everything in between. Science, networking, and maybe a little fun—strictly evidence-based, of course! #HeadAndNeckCancer @PierluigiBonomo

Hot of the press @IJROBP: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial Full text here: doi.org/10.1016/j.ijro…

Join us for the Practical guide to combine novel systemic therapies and radiation therapy pre-meeting course! 🗓 2 May 2025 | 📍 Straus 1-2 👉 Watch & register: bit.ly/40qzPYA #ESTRO25 #radonc #OncoAlert @OncoAlert

Now out in @JCO_ASCO the results of our global collaboration🌎 led by @matteolambe showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis - a thread👇🏻🧵 @OncoAlert ascopubs.org/doi/10.1200/JC…

Be careful while mentioning dietary supplements for your curative breast cancer patients. @SABCSSanAntonio

📚For everyone interested in combination strategy: don’t miss this multidisciplinary course! I’ll be waiting for you🫵🏻

One is excessive, but which one? #SABCS24 de-escalation summary👇

Presented at #SABCS24: Interim results from the EUROPA trial: Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer thelancet.com/journals/lanon…

#SABCS24 @Icro_Meattini presents interim analysis of the Europa trial. Older women with stage I lo KI67. HR+ BC Rand to RT vs ET. 24 mo FU. No recurrences yet. RT less toxic, 12% stopped ET. 850 enrolled, need more data and longer FU. Pub today in lancet oncol. @OncoAlert

💕 Important findings on risk-reducing surgeries & survival in young #BRCA carriers with #BreastCancer presented by the @matteolambe at #SABCS24. Crucial evidence shaping future care! 👏👏 @OncoAlert @SABCSSanAntonio

EUROPA trial is out in Lancet Oncology Excellent work @Icro_Meattini thelancet.com/journals/lanon…

🔥off the press👉 We have defined a new cardiac anatomical region at risk for radiotherapy The cardiac avoidance area is described and an atlas provided to facilitate implementation @KathrynBanfill @TheChristieNHS @MCRCnews jtocrr.org/article/S2666-…

🧬Cancer types and genes associated with germline mutations 👇 @ASCO @OncoAlert @JCOPO_ASCO #cancer #oncology #genetics #MedX